Help paying · Medicare negotiated price · pharmacy cost · cycle 2027
Austedo (deutetrabenazine): where help paying exists, what Medicare negotiated and what pharmacies pay
Medicare's negotiated price for a 30-day supply is $4,093 on January 1, 2027. ClinicalTrials.gov lists 2 recruiting trials that name deutetrabenazine.
Every package we can price
Per-unit prices (per each unit, as the files state). "Scheduled" is a price the CMS file already dates for the future.
| NDC | Product | Unit | Negotiated now | Scheduled | NADAC | Share |
|---|---|---|---|---|---|---|
| 68546-0170-60 | AUSTEDO (TM) TABLETS 6 MG 60 | EA | n/a | $50.27 | $83.27 | - |
| 68546-0171-60 | AUSTEDO (TM) TABLETS 9 MG 60 | EA | n/a | $56.56 | $93.83 | - |
| 68546-0172-60 | AUSTEDO (TM) TABLETS 12 MG 60 | EA | n/a | $75.40 | $125 | - |
| 68546-0470-56 | AUSTEDO XR TAB 6MG 30 | EA | n/a | $50.27 | $83.14 | - |
| 68546-0471-56 | AUSTEDO XR TAB 12MG 30 | EA | n/a | $101 | $167 | - |
| 68546-0472-56 | AUSTEDO XR TAB 24MG 30 | EA | n/a | $151 | $250 | - |
| 68546-0473-56 | AUSTEDO XR TAB 30MG 30 | EA | n/a | $201 | $332 | - |
| 68546-0474-56 | AUSTEDO XR TAB 36MG 30 | EA | n/a | $251 | $417 | - |
| 68546-0475-56 | AUSTEDO XR TAB 42MG 30 | EA | n/a | $302 | $499 | - |
| 68546-0476-56 | AUSTEDO XR TAB 48MG 30 | EA | n/a | $302 | $503 | - |
| 68546-0477-29 | AUSTEDO XR TAB 12-18-24-30MG TPACK | EA | n/a | $151 | $249 | - |
| 68546-0479-56 | AUSTEDO XR TAB 18MG 30 | EA | n/a | $151 | $251 | - |
| 68546-0490-52 | AUSTEDO XR TAB 6/12/24MG KIT 42T | n/a | n/a | $101 | n/a | no NADAC price |
When could a generic arrive
Each date below is an upper bound from listed patent and exclusivity dates, not a forecast of when a generic will launch. Basis: latest of all listed patent and exclusivity expiries in this Orange Book edition; an upper bound from listed dates only, not a forecast of launch (litigation, settlements, delisting, tentative approvals and 180-day status are not modelled).
| Application | Product | Latest listed patent expiry | Latest listed exclusivity expiry | Latest of the two | Set by |
|---|---|---|---|---|---|
| NDA208082 | Austedo (tm) Tablets 12 Mg 60, Austedo (tm) Tablets 6 Mg 60, Austedo (tm) Tablets 9 Mg 60 | September 15, 2038 | none listed | September 15, 2038 | patent 11179386 with its pediatric extension; 84 dated entries listed |
| NDA216354 | Austedo Xr Tab 12-18-24-30mg Tpack, Austedo Xr Tab 12mg 30, Austedo Xr Tab 18mg 30, Austedo Xr Tab 24mg 30 and 5 more | June 10, 2041 | none listed | June 10, 2041 | patent 11311488; 184 dated entries listed |
Source: FDA Orange Book data files, edition September 2026, read November 7, 2026; patent listings are as submitted by applicants and not verified by FDA. FDA data file.
Medicare Part D spending
CMS's Medicare Part D spending dataset reports gross spending on Austedo of $1.07 billion in 2024, across 162,212 claims and 18,418 beneficiaries. CMS's dataset states spending is gross drug cost and does not reflect manufacturers' rebates or other price concessions. Spending is the total paid by Medicare, plans and beneficiaries for the drug's claims, not what a patient pays.
| Year | Gross spending | Claims | Beneficiaries | Average spending per claim |
|---|---|---|---|---|
| 2024 | $1.07 billion | 162,212 | 18,418 | $6,577 |
| 2023 | $1.12 billion | 166,182 | 18,283 | $6,760 |
| 2022 | $890.37 million | 139,091 | 15,889 | $6,401 |
| 2021 | $666.00 million | 111,686 | 12,695 | $5,963 |
| 2020 | $530.46 million | 93,443 | 10,535 | $5,677 |
Source: CMS Medicare Part D spending by drug (data-year-2024, modified 2026-06-25), read November 7, 2026. CMS dataset page. All manufacturers combined; the figures are a drug-level aggregate of claims and say nothing about a formulary or coverage.
Rare-disease (orphan) designations
The FDA's orphan drug database lists 1 designation for deutetrabenazine. A designation is not an approval and not a statement that the drug treats the condition; the status column is the database's own.
| Designated | Designated use | Status | Sponsor |
|---|---|---|---|
| January 13, 2015 | Treatment of Tourette syndrome in the pediatric population (defined as 0 through 16 years of age) | Designated | TEVA Pharmaceuticals |
Source: FDA Orphan Drug Designations and Approvals database, read November 7, 2026. FDA orphan drug search.
Medicaid use by state
CMS's State Drug Utilization Data records, for 2025, how many prescriptions each state's Medicaid program paid for under this drug's packages and what it reimbursed. The 10 states with the largest reimbursement are shown of 30 with data. Reimbursement is before the rebates manufacturers pay states, so it is not a net cost and not a price a patient pays.
| State | Medicaid-paid prescriptions | Medicaid reimbursed | Covers |
|---|---|---|---|
| CA | 2,333 | $25,685,048 | Fee-for-service only |
| OH | 1,657 | $18,577,890 | Fee-for-service only |
| TX | 1,293 | $13,894,454 | Fee-for-service only |
| NY | 1,140 | $13,387,938 | Fee-for-service only |
| PA | 891 | $10,200,995 | All record types |
| NC | 863 | $9,299,294 | Fee-for-service only |
| LA | 730 | $8,521,701 | Fee-for-service only |
| FL | 715 | $7,981,856 | Fee-for-service only |
| AZ | 576 | $6,189,001 | All record types |
| MI | 466 | $5,732,347 | Fee-for-service only |
Where the publisher suppresses small managed-care cells, a state's figure covers fee-for-service claims only and understates use (49 state and package figures are marked that way here). A state missing from the table means its figures were suppressed or not reported, not zero use. 183 older-year figures are held and left out of the table.
Source: CMS State Drug Utilization Data (State Drug Utilization Data 2025, modified 2026-07-13T15:28:32Z), read November 7, 2026. CMS dataset page. State-reported data compiled by CMS; aggregate by state and package, no provider or patient data.
Where help paying exists
No program in our finder currently lists this drug as open to new patients.
Label changes
The FDA file lists no non-manufacturing label change for these applications since November 11, 2025. The most recent one it lists is dated February 28, 2025 (Labeling).
Source: FDA Drugs@FDA data file, read November 7, 2026. Dates are the FDA action dates; the documents are on FDA's own site. FDA data file. All recent changes across these drugs: label changes feed.
Clinical trials recruiting
ClinicalTrials.gov lists 2 interventional trials that name deutetrabenazine and are recruiting. By phase: Phase 4: 2. The 2 most recently updated are below. A listing is not an offer of free drug and not medical advice. Whether a trial fits is decided by the study team and your own clinician.
| Trial | Title and conditions | Phase | Lead sponsor | Last updated | Countries |
|---|---|---|---|---|---|
| NCT07105111 | A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) InhibitorSchizophrenia; Schizoaffective Disorder; Bipolar Disorder | Phase 4 | Neurocrine Biosciences | September 18, 2026 | United States |
| NCT06997198 | Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental DisabilitiesTardive Dyskinesia; Intellectual Disability; Developmental Disabilities | Phase 4 | University Hospitals Cleveland Medical Center | July 6, 2026 | United States |
Source: ClinicalTrials.gov, registry data processed November 6, 2026, summarized and trimmed by OmniRx. Search on ClinicalTrials.gov.
Questions
What is the Medicare negotiated price of Austedo?
The CMS file publishes $4,093 from January 1, 2027. This is a price CMS agreed with the manufacturer for Medicare Part D, not what a person pays at the counter.
How does the negotiated price compare with what pharmacies pay?
The two CMS files do not give a comparable per-unit price for this drug.
Is there help paying for Austedo?
No program in our finder lists this drug yet.
When could a generic version of Austedo arrive?
For Austedo, the FDA's Orange Book (edition September 2026) lists these latest patent or exclusivity expiry dates by application: NDA208082, September 15, 2038; NDA216354, June 10, 2041. Each date is an upper bound from listed patent and exclusivity dates, not a forecast of when a generic will launch. Basis: latest of all listed patent and exclusivity expiries in this Orange Book edition; an upper bound from listed dates only, not a forecast of launch (litigation, settlements, delisting, tentative approvals and 180-day status are not modelled).
Can I join a clinical trial for Austedo?
ClinicalTrials.gov lists 2 recruiting interventional trials that name deutetrabenazine (registry data processed November 6, 2026). A listing is not an offer of free drug and not medical advice. Whether a trial fits is decided by the study team and your own clinician.
How much does Medicare Part D spend on Austedo?
CMS's Medicare Part D spending dataset reports gross spending on Austedo of $1.07 billion in 2024, across 162,212 claims and 18,418 beneficiaries. CMS's dataset states spending is gross drug cost and does not reflect manufacturers' rebates or other price concessions. Spending is the total paid by Medicare, plans and beneficiaries for the drug's claims, not what a patient pays.
For developers: this drug as data
One call returns price, generic-entry upper bound, label history, recalls, trials, assistance, and where facts exist the FDA safety program (REMS), DEA schedule, orphan designations, safety notices and Medicaid use by state, each with receipts.
Example file: https://omnirx.org/api/v1/dossier/austedo.json
The licence page sets out what a data licence covers, and the API page documents these files.
Evaluation files with receipts; contract may change; not clinical advice.
Sources and terms. CMS Medicare Drug Price Negotiation Program data file (read November 6, 2026; the CMS page states no licence or restriction); CMS NADAC from data.medicaid.gov under the labels in the OmniRx licence ledger; program details read from each program's own pages; CMS Medicare Part D spending by drug; FDA Drugs@FDA and Orange Book data files; ClinicalTrials.gov registry data. Figures are stored with their sources in the OmniRx library (edition 2026-11). Free to cite with attribution. Not medical, legal or financial advice. Report an error through the contact page. Licence the data.